Abbott Synthroid
Executive Summary
Abbott submits NDA for thyroid hormone agent Synthroid two weeks ahead of FDA's Aug. 14 deadline for approved applications for levothyroxine products. Under an FDA guidance issued in July, Synthroid will be subject to phased-down production levels until the NDA is approved (1"The Pink Sheet" July 16, p. 16)
You may also be interested in...
FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials